Castle Biosciences, Inc.

NasdaqGM:CSTL 株式レポート

時価総額:US$796.8m

Castle Biosciences 過去の業績

過去 基準チェック /36

Castle Biosciencesの収益は年間平均-32.3%の割合で減少していますが、 Healthcare業界の収益は年間 増加しています。収益は年間5.3% 37.3%割合で 増加しています。 Castle Biosciencesの自己資本利益率は1.4%であり、純利益率は1.9%です。

主要情報

-32.3%

収益成長率

-33.4%

EPS成長率

Healthcare 業界の成長8.5%
収益成長率37.3%
株主資本利益率1.4%
ネット・マージン1.9%
前回の決算情報30 Sep 2024

最近の業績更新

Recent updates

Are Investors Undervaluing Castle Biosciences, Inc. (NASDAQ:CSTL) By 49%?

Oct 15
Are Investors Undervaluing Castle Biosciences, Inc. (NASDAQ:CSTL) By 49%?

Castle Biosciences: Inflection Into Profitability

Aug 16

Upgrade: Analysts Just Made A Meaningful Increase To Their Castle Biosciences, Inc. (NASDAQ:CSTL) Forecasts

Aug 11
Upgrade: Analysts Just Made A Meaningful Increase To Their Castle Biosciences, Inc. (NASDAQ:CSTL) Forecasts

Castle Biosciences, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Aug 08
Castle Biosciences, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Castle Biosciences, Inc.'s (NASDAQ:CSTL) 28% Share Price Surge Not Quite Adding Up

Aug 04
Castle Biosciences, Inc.'s (NASDAQ:CSTL) 28% Share Price Surge Not Quite Adding Up

Is Castle Biosciences (NASDAQ:CSTL) A Risky Investment?

Jul 12
Is Castle Biosciences (NASDAQ:CSTL) A Risky Investment?

Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is On The Mark

Apr 30
Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is On The Mark

Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects

Jan 27
Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects

Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans

Oct 31
Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans

Earnings Working Against Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Following 36% Dive

Jun 13
Earnings Working Against Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Following 36% Dive

Analysts Just Published A Bright New Outlook For Castle Biosciences, Inc.'s (NASDAQ:CSTL)

Aug 14
Analysts Just Published A Bright New Outlook For Castle Biosciences, Inc.'s (NASDAQ:CSTL)

Castle Biosciences Q2 2022 Earnings Preview

Aug 08

収支内訳

Castle Biosciences の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqGM:CSTL 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Sep 24312619453
30 Jun 24288-318854
31 Mar 24251-3118253
31 Dec 23220-5718054
30 Sep 23192-7617452
30 Jun 23168-8916850
31 Mar 23152-7215949
31 Dec 22137-6714345
30 Sep 22124-5313043
30 Jun 22110-4411440
31 Mar 2298-529934
31 Dec 2194-318730
30 Sep 2186-307725
30 Jun 2178-236620
31 Mar 2168-155516
31 Dec 2063-104813
30 Sep 2063-34312
30 Jun 206373810
31 Mar 20616359
31 Dec 19523307
30 Sep 19464245
30 Jun 1935-6215
31 Mar 1928-8185
31 Dec 1823-10165
31 Dec 1741-464613

質の高い収益: CSTLは 高品質の収益 を持っています。

利益率の向上: CSTL過去に利益を上げました。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: CSTL過去 5 年間で収益を上げており、収益は年間-32.3%増加しています。

成長の加速: CSTLは昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。

収益対業界: CSTL昨年収益を上げたため、昨年の収益成長をHealthcare業界 ( 10.3% ) と比較することは困難です。


株主資本利益率

高いROE: CSTLの 自己資本利益率 ( 1.4% ) は 低い とみなされます。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘